Avidity
Meredith Frie has a strong background in scientific research. Meredith began their career as a PhD candidate at Michigan State University, where they focused on their studies from August 2012 to November 2017. After completing their PhD, they joined the Salk Institute for Biological Studies as a Postdoctoral Researcher in January 2018, where they conducted research until June 2021. Currently, Meredith works as a Scientist at Avidity Biosciences, Inc. starting from June 2021.
Meredith Frie earned a Doctor of Philosophy (Ph.D.) degree in Cell and Molecular Biology from Michigan State University between 2012 and 2017. Prior to that, they completed their undergraduate studies at UC San Diego, where they obtained a Bachelor of Science (BS) degree in Human Biology. The precise years of their undergraduate education are not provided.
This person is not in the org chart
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.